Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier

被引:45
|
作者
Luker, GD
Rao, VV
Crankshaw, CL
Dahlheimer, J
PiwnicaWorms, D
机构
[1] WASHINGTON UNIV,SCH MED,DEPT RADIOL,LAB MOL RADIOPHARMACOL,ST LOUIS,MO 63110
[2] WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110
关键词
D O I
10.1021/bi971931z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The multidrug resistance (MDR1) P-glycoprotein functions as a broad specificity efflux transporter of structurally diverse natural product and xenobiotic compounds. P-glycoprotein also is an important component of the functional blood-brain barrier. To enable further studies of function and modulation of MDR1 P-glycoprotein in vitro and in vivo, two novel phosphine technetium(III) complexes were designed and characterized: trans-[2,2'-(1,2-ethanediyldiimino)bis(1,5-methoxy-5-methyl-4-oxohexenyl)]bis[methylbis(3-methoxy-1-propyl)phosphine]Tc(III) (Tc-Q58) and trans-[5,5'-(1,2-ethanediyl diimino)bis(2-ethoxy-2-methyl-3-oxo-4-pentenyl)]bis[dimethyl(3-methoxy-1-propyl)phosphine)]Tc(III) (Tc-Q63). In human drug-sensitive KB 3-1 cells and multidrug-resistant KB 8-5 and 8-5-11 derivative cell lines, expressing nonimmunodetectable, low, and high levels of MDR1 P-glycoprotein, respectively, accumulation of Tc-Q58 and Tc-Q63 was inverse to expression of the transporter. Differences between drug-sensitive and multidrug-resistant cells, while detectable at picomolar concentrations of each radiopharmaceutical, were independent of tracer concentration, Ratios of tracer accumulation in KB 3-1 and 8-5 cells were 62.3 and 48.1 for Tc-Q58 and Tc-Q63, respectively. Cell contents of Tc-Q58 and Tc-Q63 were enhanced up to 60-fold in MDR cells by known modulators of MDR1 P-glycoprotein, while drugs not in the multidrug-resistant phenotype had no effect on their accumulation. In KB 8-5 cells, potency of modulators was GF120918 much greater than cyclosporin A > verapamil. Accumulation of Tc-Q58 and Tc-Q63 in Sf9 insect cells infected with a recombinant baculovirus containing human MDR1 P-glycoprotein was reduced in a GF120918-reversible manner (EC50 less than or equal to 70 nM) compared with cells infected with a wild-type baculovirus. By contrast, cell contents of Tc-Q58 or Tc-Q63 in Sf9 cells expressing the homologous MDR3 P-glycoprotein did not differ from wild-type virus, Demonstrating molecular targeting of these complexes in vivo, distribution and retention of Tc-Q58 in brain tissue of FVB mice treated with a saturating dose of GF120918 and mice deficient in the mdr1a gene [mdr1a (-/-)] were enhanced 180% and 520% over control, respectively. Exploiting the gamma-emission spectrum of Tc-99m, increased uptake of Tc-Q58 in brain tissue of mdr1a (-/-) mice was readily detected noninvasively by scintigraphic imaging. Thus, both Tc-Q58 and Tc-Q63 are demonstrated to be substrates for transport by MDR1 P-glycoprotein, broadening the specificity of this transporter to include phosphine-containing metal complexes. As shown with Tc-Q58, these Q complexes can be used to detect transport activity and modulation of MDR1 P-glycoprotein in vitro and to directly monitor the functional status of P-glycoprotein at the blood-brain barrier in vivo.
引用
收藏
页码:14218 / 14227
页数:10
相关论文
共 50 条
  • [41] TGF-β1 Regulation of Multidrug Resistance P-glycoprotein in the Developing Male Blood-Brain Barrier
    Baello, Stephanie
    Iqbal, Majid
    Bloise, Enrrico
    Javam, Mohsen
    Gibb, William
    Matthews, Stephen G.
    ENDOCRINOLOGY, 2014, 155 (02) : 475 - 484
  • [42] Imaging P-glycoprotein at the human blood-brain barrier - Reply
    Unadkat, Jashvant D.
    Link, Jeanne M.
    Mankoff, David A.
    Muzi, Mark
    Collier, Ann C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (03) : 303 - 304
  • [43] P-glycoprotein activity in an in vitro blood-brain barrier model
    Joly, B
    Fardel, O
    Lecureur, V
    Chesne, C
    Puozzo, C
    Guillouzo, A
    BIOLOGY AND PHYSIOLOGY OF THE BLOOD-BRAIN BARRIER: TRANSPORT, CELLULAR INTERACTIONS, AND BRAIN PATHOLOGIES, 1996, 46 : 191 - 196
  • [44] Inhibition of P-Glycoprotein Function by Procyanidine on Blood-Brain Barrier
    He, Ling
    Zhao, Chuan
    Yan, Ming
    Zhang, Lu-Yong
    Xia, Yuan-Zheng
    PHYTOTHERAPY RESEARCH, 2009, 23 (07) : 933 - 937
  • [45] Regulation of Multidrug Resistance P-Glycoprotein in the Developing Blood-Brain Barrier: Interplay between Glucocorticoids and Cytokines
    Iqbal, M.
    Baello, S.
    Javam, M.
    Audette, M. C.
    Gibb, W.
    Matthews, S. G.
    JOURNAL OF NEUROENDOCRINOLOGY, 2016, 28 (03)
  • [46] P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine P-glycoprotein knockout model
    Mealey, Katrina L.
    Greene, Stephen
    Bagley, Rodney
    Gay, John
    Tucker, Russ
    Gavin, Patrick
    Schmidt, Kari
    Nelson, Frederick
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (06) : 1073 - 1079
  • [47] Functional expression and localization of P-glycoprotein at the blood brain barrier
    Bendayan, R
    Lee, G
    Bendayan, M
    MICROSCOPY RESEARCH AND TECHNIQUE, 2002, 57 (05) : 365 - 380
  • [48] FUNCTIONAL INVOLVEMENT OF P-GLYCOPROTEIN IN BLOOD-BRAIN-BARRIER
    TATSUTA, T
    NAITO, M
    OHHARA, T
    SUGAWARA, I
    TSURUO, T
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1992, 267 (28) : 20383 - 20391
  • [49] Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine
    Drion, N
    Lemaire, M
    Lefauconnier, JM
    Scherrmann, JM
    JOURNAL OF NEUROCHEMISTRY, 1996, 67 (04) : 1688 - 1693
  • [50] Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins
    Gimenez, F
    Fernandez, C
    Mabondzo, A
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (02) : 649 - 658